Patent · US Active

FGF21 variant, fusion protein and application thereof

US11679143B2 · kind B2 · utility

0Cited by

14References

19Claims

0Family size

Assignee

SUNSHINE LAKE PHARMA CO., LTD. · CN

Inventors

Chao Chen · Edmonton, CA
Shushan LIN · Dongguan, CN
Yu LI · Fremont, US
Xiaofeng Chen · San Jose, US
Wenjia LI · Dongguan, CN
Liang Liu · Macau, CN
Zheng FU · Dongguan, CN

Key dates

Filing date	Jan 29, 2019
Grant date	Jun 20, 2023
Priority date	—
Expiry date	Jun 18, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof can significantly improve the binding ability with the target and can be used to treat metabolic diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.